Pelletization processes for pharmaceutical applications: A patent review

Recent Patents on Drug Delivery and Formulation

Volumn 5, Issue 1, 2011, Pages 61-78

  Politis, Stavros N ^a   Rekkas, Dimitrios M ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Direct pelletization; Extrusion; Hot melt; Layering; Pellets; Spheronization

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; AMOXICILLIN PULSYS; ANTIBIOTIC AGENT; BENZENESULFONAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BUDESONIDE; CARBAMAZEPINE; CARVEDILOL; CLARITHROMYCIN; DILTIAZEM; FAMCICLOVIR; GALANTAMINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MESALAZINE; METHYLPHENIDATE; METOPROLOL; MORPHINE SULFATE; MUSCARINIC RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT; NAPROXEN; PROPAFENONE; TAMSULOSIN; THEOPHYLLINE; THIOCTIC ACID; TICLOPIDINE; TOLTERODINE; TRAMADOL; UNINDEXED DRUG; VERAPAMIL; DRUG;

ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG GRANULATION; DRUG GRANULE; DRUG MIXTURE; DRUG PELLET; DRUG RELEASE; ENCAPSULATION; FREEZE DRYING; MIXER; PARTICLE SIZE; PATENT; PELLET EXTRUSION; POWDER; PRIORITY JOURNAL; SPHERONIZATION; SPRAY DRYING; TABLET COMPRESSION; CHEMISTRY; DRUG DOSAGE FORM; DRUG IMPLANT; HUMAN; REVIEW;

DOSAGE FORMS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 79954434179     PISSN: 18722113     EISSN: 18722113     Source Type: Journal    
DOI: 10.2174/187221111794109493     Document Type: Article

References (289)

1. Ghebre-Sellassie I. Pharmaceutical Pelletization Technology.Marcel Dekker: New York 1989.
2. Gu L, Liew CV, Heng PWS. Wet Spheronization by rotaryprocessing - A multistage single-pot process for producingspheroids. Drug Dev Ind Pharm 2004; 30(2): 111-123.
3. Abdul S, Chandewar AV, Jaiswal SB. A flexible technology formodified-release drugs: multiple-unit pellet system (MUPS). J Control Release 2010; 147(1): 2-16.
4. Follonier N, Doelker E. Biopharmaceutical comparison of oralmultiple unit and single unit extended release dosage forms, S.T.P.Pharm Sci 1992; 141-58.
5. Coupe AJ, Davis SS, Evans DF, Wilding IR. Do pellet formulationsempty from the stomach with food? Int J Pharm 1993; 9(1-3): 161-75.
6. Clarke GM, Newton MJ, Short MD. Gastrointestinal transit ofpellets of differing size and density. Int J Pharm 1993; 100: 81-92.
7. Devereux JE, Newton JM, Short MB. The influence of density onthe gastrointestinal transit of pellets. J Pharm Pharmacol 1990; 42:500-1.
8. Bechgaard H, Ladefoged K. Distribution of pellets in thegastrointestinal tract. Influence of transit time exerted by thedensity or diameter of pellets. J Pharm Pharmacol 1978; 30: 690-2.
9. Tuleu C, Andrieux C, Boy P, Chaumeil JC. Gastrointestinal transitof pellets in rats: effect of size and density. Int J Pharm 1999; 180:123-31.
10. Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J. Design of anew multiple-unit controlled-release formulation of metoprolol -Metoprolol CR. Eur J Clin Pharmacol 1988; 33: S3-S7.
11. Amighi K, Timmermans J, Puigdevall J, Baltes E, Moës AJ. Peroralextended release film coated pellets as a means to overcomephysicochemical and biological drug related problems: Part I:in vitro development and evaluation. Drug Dev Ind Pharm 1998;24: 509-514.
12. Ghebre-Sellassie I, Gordon RH, Nesbitt RU, Fawzi MB. Evaluationof acrylic-based modified-release film coating. Int J Pharm 1987;37: 211-8.
13. Saigal N, Baboota S, Ahuja A. Ali J. Site specific chronotherapeuticdrug delivery systems: A patent review. Recent Pat DrugDeliv Form 2009; 3: 64-70.
14. Béchard SR, Leroux JC. Coated pelletized dosage form: Effect ofcomparison on drug release. Drug Dev Ind Pharm 1992; 18: 1927-44.
15. McGinity JW. Aqueous Polymeric Coatings for Pharmaceutical Dosage forms 2nd ed. Marcel Dekker: USA 1997.
16. Vervaet C, Baert L, Remon JP. Extrusion-spheronisation: Aliterature review. Int J Pharm 1995; 116(2): 131-46.
17. Qiu Y, Chen Y, Zhang G, Liu L, Porter W. Developing Solid OralDosage Forms. Pharmaceut Theory Prac Elsevier: USA 2009.
18. Sotthivirat S, Haslam JL, Stella VJ. Controlled porosity-osmoticpump pellets of a poorly water-soluble drug using sulfobutylethercyclodextrin, (SBE)7M-CD, as a solubilizing and osmotic agent. JPharm Sci 2007; 96(9): 2364-74.
19. Ghebre-Sellassie I, Gordon RH, Fawzi MB, Nesbitt RU. Evaluationof a high-speed pelletization process and equipment. Drug Dev IndPharm 1985; 11: 1523-41.
20. Ghebre-Sellassie I, Knoch A. Pelletization techniques. In:Swarbrick J, Boylan JC, Eds. Encyclopedia PharmaceutTechnol.New York: Marcel Dekker 1995: 369-94.
21. Womack JP, Jones DT, Roos D. The Machine that changed theworld: The Story of Lean Production. Harper Collins: New York 1990.
22. Yusuf YY, Adeleye EO. A comparative study of lean and agilemanufacturing with a related survey of current practices in the UK.Int J Prod Res 2002; 40(17): 4545-62.
23. Yusuf YY, Sarhadi M, Gunasekaran A. Agile manufacturing: Thedrivers, concepts and attributes. Int J Prod Econ 1999; 62(1-2): 33-43.
24. Shimizu T, Nakano Y, Morimoto S, Tabata T, Hamaguchi N, Igari Y. Formulation study for lansoprazole fast-disintegrating tablet. I.Effect of compression on dissolution behavior. Chem Pharm Bull 2003a; 51(8): 942.
25. Shimizu T, Kameoka N, Iki H, Tabata T, Hamaguchi N, Igari Y.Formulation study for lansoprazole fast-disintegrating tablet. II.Effect of triethyl citrate on the quality of the products. Chem PharmBull 2003b; 51(9): 1029-35.
26. Shimuzu T, Sugaya M, Nakano Y, Izutsu D, Mizukami Y, Okochi K. Formulation study for lansoprazole fast-disintegrating tablet: III,Design of rapidly disintegrating tablets. Chem Pharm Bull 2003c;51: 1121-7.
27. Podczeck F, Newton JM. Evaluation of a three-dimensional shapefactor for the quantitative assessment of the sphericity and surfaceroughness of pellets. Int J Pharm 1995; 124: 253-9.
28. Podczeck F, Newton JM. A shape factor to characterize the qualityof spheroids. J Pharm Pharmacol 1994; 46: 82-5.
29. Ghebre-Sellassie I, Martin C. Pharmaceutical ExtrusionTechnology. Drugs and the Pharmaceutical Sciences. MarcelDekker: New York 2003.
30. Trivedi NR, Rajan MG, Johnson JR, Shukla AJ. Pharmaceuticalapproaches to preparing pelletized dosage forms using theextrusion-spheronization process. Crit Rev Ther Drug Carrier Syst 2007; 24(1): 1-40.
31. Dukić-Ott A, Thommes M, Remon JP, Kleinebudde P, Vervaet C. Production of pellets via extrusion-spheronisation without theincorporation of microcrystalline cellulose. Eur J Pharm Biopharm 2009; 71: 38-46.
32. McConelli EL, Pygall SR, Ward R, Seller C, An industrial insightinto pellet manufacturing by extrusion spheronization. Drug DelivTech 2010; 10(6): 50-4.
33. Erkoboni, D.F., Fiore, S.A. Wheatley, T.A. Microcrystallinecellulose spheronization composition. US5725886 (1998).
34. Dukic, A.L., Vervaet, C., Remon, J.P., Altieri, P.A., Foreman, P.B. Use of debranched starch in extusion-spheronizationpharmaceutical pellets. US20060246192 (2006).
35. Remon, J.P., Vervaet C. Foreman, P. Vaginal pellets comprisingdebranched starch. WO2010048389 (2010).
36. Remon, J.P. Vervaet C., Foreman, P. Pharmaceutical pelletscomprising modified starch and therapeutic applications therefor. US20100105784 (2010).
37. Carli, F., Bresciani, M., Canal, T., Gambini, P. Pharmaceuticalcompositions in form of polymeric microparticles obtained byextrusion and spheronization. US6355273 (2002).
38. Podczeck, G. Pellet formulation comprising colloidal silicondioxide. US20090311331 (2009).
39. Gil, A., Ouattara, M.D., Bertocchi, L. Extruder for the productionof spheroidal or spheroid particles. US20060182836 (2006).
40. Hellen, L., Husson, I., Kristoffersson, E., Yliruusi, J. Process for thepreparation of drug pellets. US5709885 (1998).
41. Strong, B., Kloemkes, M., Bachmann D. Spherical pelletformulations. US20060153908 (2006).
42. Ullah, I., Wiley, G.J. High drug load acid labile pharmaceuticalcomposition. US20020076438 (2002) & US7122207 (2006).
43. Bartholomaeus, J.H, Ziegler, I. Process for preparing pelletscontaining up to 90wt.% of a pharmaceutical active ingredient. US6558704 (2003).
44. Howard, J.R.; Delargy A.M. Pharmaceutical compositioncontaining high drug load and method for preparing same.US5049394 (1991).
45. Appel, L.E., Curatolo, W.J., Herbig, S.M., Nightingale, J.A.S., Thombre, A.G. Controlled release by extrusion of solid amorphousdispersions of drug. US7550158 (2009).
46. Domingos Da Silva Santos, J.; Ferreira Da Silva Lopes, M.A., Alves Da Silva, M. Hydroxyapatite and bioglass-based pellets,production process and applications of thereof. WO2010021559(2010).
47. Breitkreutz J, Bornhöft M, Wöll F, Kleinebudde P. Pediatric drugformulations of sodium benzoate: I. Coated granules with ahydrophilic binder. Eur J Pharm Biopharm 2003; 56(2): 247-53.
48. Breitkreutz J, El-Saleh F, Kiera C, Kleinebudde P, Wiedey W. Pediatric drug formulations of sodium benzoate: II. Coated granuleswith a lipophilic binder. Eur J Pharm Biopharm 2003; 56: 255-60.
49. Reitz C, Strachan C, Kleinebudde P. Solid lipid extrudates asextended-release matrices: The effect of surface structure on drugrelease properties. Eur J Pharm Sci 2008; 35: 335-43.
50. Krause J, Thommes M, Breitkreutz J. Immediate release pelletswith lipid binders obtained by solvent-free cold extrusion. Eur JPharm Biopharm 2009; 71: 138-44.
51. Breitkreutz, J., Matilainen, J. Lipid pellets with enhanced tastemasking.WO2010037543 (2010).
52. Knovel® Engineering cases: Twin-screw extrusion scales down forpharma and nanotechnology. http://engineeringcases.knovelblogs.com/2010/06/24/twin-screw-extrusion-scales-downfor-pharma-and-nanotech/ (2010).
53. Pourdeyhimi, B. Fiber-based nano drug delivery systems (NDDS).US7491407 (2009).
54. Gamlen MJ. Pellet manufacture for controlled release. Manuf Chem 1985; 56, 6: 55-59.
55. Nastruzzi C, Cortesi R, Esposito E, Genovesi A, Spadoni A, Vecchio C.; Menegatti E. Influence of formulation and processparameters on pellet production by powder layering technique.AAPS Pharm Sci Tech 2000; 1(2): article 9.
56. Behzadi SS, Toegel S, Viernstein H. Innovations in coatingtechnology. Recent Pat Drug Deliv Formul 2008; 2(3): 209-30.
57. Bär, H., Fürst, T., Rupp, T., Renner, G., Gottschalk, M. Controlledrelease pharmaceutical composition with resistance against theinfluence of ethanol employing a coating comprising a polymermixture and excipients. WO2010105673 (2010).
58. Bose S, Bogner RH. Solventless photocurable film coating:Evaluation of drug release, mechanical strength, and photostability.AAPS Pharm Sci Tech 2007; 8(3): 57.
59. Khanvilkarv VV, Pawar AS, Bageshwar DV, Kadam VJ. Pharmaceutical solventless coatings. J Pharm 2010; 3(7): 1541-6.
60. Obara S, Maruyama N, Nishiyama Y, Kokubo H. Dry coating: Aninnovative enteric coating method using a cellulose derivative. EurJ Pharm Biopharm 1999; 47: 51-9.
61. Cerea M, Zheng W, Young C, McGinity JW. A novel powdercoating process for attaining taste masking and moisture protectivefilms applied to tablets. Int J Pharm 2000; 279: 127-39.
62. Pearnchob N, Bodmeier R. Dry powder coating of pellets withmicronized Eudragit RS for extended drug release. Pharm Res 2003a; 20(12): 1970-1976.
63. Pearnchob N, Bodmeier R. Dry polymer powder coating andcomparison with conventional liquid-based coatings for Eudragit(R) RS, ethyl cellulose and shellac. Eur J Pharm Biopharm 2003b;56(3): 363-9.
64. Pearnchob N, Bodmeier R. Coating of pellets with micronized ethylcellulose particles by a dry powder coating technique. Int J Pharm 2003c; 268 (1, 2): 1-11.
65. Bilancetti L, Poncelet D, Loisel C, Mazzitelli S, Nastruzzi C. Astatistical approach to optimize the spray drying of starch particles:Application to dry powder coating. AAPS Pharm Sci Tech 2010;11(3): 1257-67.
66. Brown, S.R., Reeves, L.A., Stantiforth, J.N. Method and apparatusfor the coating of substrates for pharmaceutical use. US6783768(2004), US20050003074 (2005) & US7153538 (2006).
67. Hogan, J.E., Stantiforth, J.N., Reeves, L., Page, T. Electrostaticcoating. US6117479 (2000), US20020034592 (2002b) &US7070656 (2006c).
68. Hogan, J.E., Page, T., Reeves, L., Stantiforth, J.N. Powder coatingcomposition for electrostatic coating of pharmaceutical substrates.US6406738 (2002a), US20060280943 (2006a) & US7008668(2006b).
69. Hogan, J.E., Page, T., Reeves, L., Stantiforth, J.N. Method andapparatus for the coating of substrates for pharmaceutical use.US20030138487 (2003).
70. Hallett, M.D. Method and apparatus for applying powder in apattern to a substrate. US20060099350 (2006).
71. Newman, M., Impey, B., Henley, T., Jennings, D, Hallett, M. Method and apparatus for the application of powder material tosubstrate. US20070028790 (2007).
72. Phoqus Group plc. Annual Report and Accounts (2006).
73. Luo Y, Zhu J, Ma Y, Zhang H. Dry coating, a novel coatingtechnology for solid pharmaceutical dosage forms. Int J Pharm 2008; 358(1, 2): 16-22.
74. Bodmeier R, McGinity JW. Dry coating of solid substrates withpolymeric powders. Drug Deliv Technol 2005; 5, 9.
75. Zhu, J., Zhang, H. Fluidization additives to fine powders. US6833185 (2004).
76. Zhu J, Zhang H. Ultrafine powder coatings: an innovation. PowderCoat 2005; 16: 39-47.
77. Zhu, J., Luo, Y.F., Ma, Y., Zhang, H. Direct coating solid dosageforms using powdered materials. US20070128274 (2007).
78. Wang JZY, Bogner RH. Solvent-free film coating using a novelphotocurable polymer. Int J Pharm 1995; 119: 81-9.
79. Savage, G.V., Clevenger, J.M. Radiation cured drug releasecontrolling membrane. US5532287 (1996a).
80. Savage, G.V., Clevenger, J.M. Method of using a radiation cureddrug release controlling membrane. US5545442 (1996b).
81. Bose S, Kelly B, Bogner RH. Design space for a solventlessphotocurable pharmaceutical coating. J Pharm Innov 2006; 1(1):44-53.
82. Bose S, Bogner RH. Solventless pharmaceutical coating processes:A review. Pharm Dev Technol 2007; 12(2): 115-31.
83. Bose S, Bogner RH. Solventless visible light-curable coating: I.Critical formulation and processing parameters Int J Pharm 2010;393(1-2): 32-40.
84. Corazza ML, Filho LC, Dariva C, Modeling and simulation of rapidexpansion of supercritical solutions. Braz J Chem Eng 2006; 23(3):417-25.
85. Tsutsumi A, Nakamoto S, Mineo T, Yoshida K. A novel fluidizingcoating of fine particles by rapid expansion of supercritical fluids.Powder Technol 1995; 85: 275-8.
86. Benoit, J., Herve, R., Curt, T. Method of coating particles andcoated spherical particles. US6087003 (2000).
87. Thies C, Dos Santos RI, Richard J, VandeVelde V, Rolland H, Benoit JP. A supercritical fluid-based coating technology 1: Processconsiderations. J Microencapsul 2003; 20(1): 87-96.
88. Dos Santos RI, Thies C, Richard J, Le Meurlay D, Gajan V, VandeVelde V, et al. A supercritical fluid-based coatingtechnology. 2: Solubility considerations. J Microencapsul 2003;20(1): 97-109.
89. Ziegler, G.R., Wysk, R.A., Frank, M.C. Coating foods andpharmaceuticals with an edible polymer using carbon dioxide.US6723363 (2004).
90. Parikh DM. Handbook of Pharmaceutical Granulation Technology 2nd ed, Taylor and Francis: New York 2005.
91. Platteeuw, J. Pharmaceutical pellets comprising tamsulosin.US7018658 (2006).
92. G.W. Inhalation composition containing lactose pellets.US6183782 (2001).
93. Farago, G., Fazekas, P., Gunther, G., Kocsis, L., Pataki K. Processfor the preparation and surface coating of pellets. WO2007135470(2007).
94. Heng PWS, Wan LSC, Tan YTF. Optimization of spheroidproduction by centrifugal rotary processing. Int J Pharm 1996; 143:107-112.
95. Politis, S., Chalkias, G. Process for producing rapidly disintegratingspheroids (pellets), granules and/or mixtures there of process forproducing rapidly disintegrating spheroids (pellets),granules and/ormixtures thereof. WO2010115475 (2010).
96. Heinicke, G. Venlafaxine formulations and methods of preparingthe same. US7744924 (2010).
97. Kraubsauer, E. Gerber, F., Schluetermann, B. Orally disintegratingtablets for the treatment of pain. WO2010081722 (2010).
98. Kwang, H., Shin, Y.H., Bin, S.A., Kim, J.J. Extended release pelletformulation of Alpha1-receptor antagonist and process for thepreparation thereof. WO2007021101 (2007).
99. Mulye, N. Controlled release pharmaceutical compositions.WO2009042778 (2009).
100. Orapin P.R. Micropellet containing pellets and method of preparingsuch pellets. WO2005115340 (2005) & US20080254115 (2008).
101. Vehring R. Pharmaceutical particle engineering via spray drying.Pharm Res 2008; 25(5): 999-1022.
102. Sollohub K, Cal K. Spray drying technique: II. Current applicationsin pharmaceutical technology. J Pharm Sci 2010; 99(2): 587-97.
103. Cal K, Sollohub K. Spray drying technique. I: Hardware andprocess parameters. J Pharm Sci 2010; 99(2): 575-86.
104. Lynenskjold, E., Jorgensen, L.N. Drug carrier pellet productionprocess. US20090017125 (2009).
105. Vorlop, K. D., Breford, J. Production of solid particles from a liquidmedium. DE4424998 (1994).
106. Vorlop, K. D., Pruesse, U., Breford, J. Method and device forproducing solid particles from a liquid medium. US6467699(2002).
107. Jahnzi U, Wittlich P, Hofman M, Thonart P, Vorlop KD. Newmatrices and bioencapsulation processes. Engin Manuf Biotechnol 2001; 4: 293-307.
108. McConihay, J.A., Matthews, A.E., Zerby, K.W. Microcapsules,issued for detergents however deszcribes the use of the process andutilizes pharmaceutically acceptable materials. US7435715 (2008).
109. Petereit, H.U., Bergmann, G., Lehmann, K. Method for productionof active ingredient-containing pellets. US20040247687 (2004).
110. Buchmuller, J., Weyermanns, G. Device for the controlled freezingof viscous liquids. US4829783 (1989).
111. Weyermanns, G. Freezing and pelletizing process and device forpourable and flowing materials. US5694777 (1997).
112. Schvester, P. Pellet-freezing device and process. WO0168231(2001).
113. Rahman A, Ahuja A, Baboota S, Bhavna, Bali V, Saigal N, et al.Recent advances in pelletization technique for oral drug delivery.Curr Drug Deliv 2009; 6(1): 122-9.
114. Sweeney, J.F., Dea, P.C., Aimutis, W.R., Cavallini, V.M., Nelson, K.J., Metin, S. Pellet systems for preparing beverages. US7615246 (2009).
115. Hoffmann, H.R., Asmussen, B. Rapidly decomposing chitosanbasedpellets. US6770300 (2004).
116. Gupta, V.K., Vaya, N. Pharmaceutical composition having casingwith multiple micro tablets. WO2005048979 (2005).
117. Durga, M.P., Appalaswamy N.R., Podile, K., Venkaiah C.N. Controlled release mucoadhesive matrix formulation containingtolterodine and a process for its preparation. WO2005105036 (2005).
118. Kontopanou, E., Politis, S. Extended release microtabletscomprising tolterodine tartate. WO2009135520 (2009).
119. Murty, M.A.; Li, B. Controlled release Budesonide minitablets.WO2010096068 (2010).
120. Serge, R., Brandon, M. Extended release delivery system.WO2003009833 (2003).
121. Martinod, S, Brandon, M. Extended release delivery system.WO200061634 (2006).
122. Rouge N, Cole ET, Doelker E, Buri P. Screening of potentiallyfloating excipients for minitablets. STP Pharm Sci 1997; 7: 386-92.
123. Bredenberg S, Nyholm D, Aquilonius SN, Nyström C. Anautomatic dose dispenser for microtablets-a new concept forindividual dosage of drugs in tablet form. Int J Pharm 2003; 261:137-46.
124. Nyström, C., Aquilonius, S.N. A method and apparatus for dosing amedical preparation. EP2055293A1 (2009).
125. Chiou WL, Riegelman S. Pharmaceutical applications of soliddispersion systems. J Pharm Sci 1971; 60(9): 1281-302.
126. Leuner C, Dressman J. Improving drug solubility for oral deliveryusing solid dispersions. Eur J Pharm Biopharm 2000; 50(1-3): 47-60.
127. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs:Early promises, subsequent problems, and recent breakthroughs. JPharm Sci 1988; 10: 1058-66.
128. Craig DQM. The mechanisms of drug release from soliddispersions in water-soluble polymers. Int J Pharm 2002; 231: 131-44.
129. Andrews GP. Advances in solid dosage form manufacturingtechnology. Philes Trans R Soc A 2007; 365: 2935-2949
130. Crowley MM, Zhang F, Repka MA., Thumma S, Upadhye SB, Battu SK, et al. Pharmaceutical applications of hot-melt extrusion:Part I. Drug Dev Ind Pharm 2007; 33: 909-26.
131. Follonier N, Doelker E, Cole ET. Evaluation of hot-melt extrusionas a new technique for the production of polymer-based pellets forextended- release capsules containing high loadings of freelysoluble drugs. Drug Dev Ind Pharm 1994; 20(8): 1323-39.
132. Follonier N, Doelker E, Cole ET. Various ways of modulating therelease of diltiazem hydrochloride from hot-melt extruded extendedrelease pellets prepared using polymeric materials. J ControlRelease 1995; 36(3): 243-50.
133. Perissutti B, Newton JM, Podczeck F, Rubessa F. Preparation ofextruded carbamazepine and PEG 4000 as a potential rapid releasedosage form. Eur J Pharm Biopharm 2002; 53(1): 125-32.
134. Perissutti B, Rubessa F, Moneghini M, Voinovich D. Formulationdesign of carbamazepine fast-release tablets prepared by meltgranulation technique. Int J Pharm 2003; 256: 53-63.
135. Yano K, Kajiyama A, Hamada M, Yamamoto K. Constitution ofcolloidal particles formed from a solid dispersion system. ChemPharm Bull 1997; 45: 1339-44.
136. Zhang F, McGinity JW. Properties of extended-release tabletsprepared by hot-melt extrusion. Pharm Dev Technol 1999; 4(2):241-50.
137. Crowley MM, Zhang F, Koleng JJ, McGinity JW. Stability ofpolyethylene oxide in matrix tablets prepared by hot-melt extrusion.Biomaterials 2002; 23(21): 4241-8.
138. Heng, W.S.P., Cheong W.S., Loh Z.H., Ray D.B., Haldar R., Anthony, Y. Meltable binder for melt granulation and/orpelletization. US20100104656 (2010).
139. Bougaret, J., Leverd, E., Ibarra, M.D. Stable solid dispersion of aderivative of Vinca alkaloid and process for manufacturing it. US20080260828 (2008).
140. Rippie EG, Johnson JR. Regulation of dissolution rate by pelletgeometry. J Pharm Sci. 1969; 58: 428-31.
141. De Brabander C, Vervaet C, Remon JP. Development andevaluation of extended release mini-matrices prepared via hot-meltextrusion. J Control Release 2003; 89: 235-47.
142. De Brabander C, Vervaet C, Van Bortel L, Remon JP. Bioavailability of ibuprofen from hot-melt extruded mini-matrices.Int J Pharm 2004; 271(1-2): 77-84.
143. Grassi M, Voinovich D, Iztok GI, Erica FE, Perissutti B, Filipovic-Grcic JJ. Preparation and in vitro / in vivo characterisation of a meltpelletised paracetamol/stearic acid extended release deliverysystem. Spectroscopy 2004; 18: 2.
144. Hamdani J, Moes AJ, Amighi K. Development and evaluation ofprolonged release pellets obtained by the melt pelletization process.Int J Pharm 2002; 245: 167-77.
145. Hamdani J, Moes AJ, Amighi K. In vitro and in vivo evaluation of anovel floating multiple unit dosage form obtained by meltpelletization. Int J Pharm 2006; 322: 96-103.
146. Liu J, Zhang F, McGinity J. Properties of lipophilic matrix tabletscontaining phenylpropanolamine hydrochloride prepared by hotmeltextrusion. Eur J Pharm Biopharm 2001; 52(2): 181-90.
147. Miyagawa Y, Okabe T, Yamaguchi Y, Miyajima M, Sato H, Sunada H. Controlled-release of diclofenac sodium from waxmatrix granule. Int J Pharm 1996; 138(2): 215-24.
148. Miyagawa Y, Sato H, Okabe T, Nishiyama T, Miyajima M, Sunada H. In vivo performance of wax matrix granules prepared by atwinscrew compounding extruder. Drug Dev Ind Pharm 1999;25(4): 429-35.
149. Montoussé C, Pruvost M, Rodriguez F, Brossard C. Extrusionspheronization manufacture of Gelucire® matrix beads. Drug DevInd Pharm 1999; 25(1): 75-80.
150. Pauli-Bruns A, Knop K, Lippold BC. Preparation of extendedrelease matrix pellets by melt agglomeration in the fluidized bed:Influence of formulation variables and modelling of agglomerategrowth. Eur J Pharm Biopharm 2010; 74(3): 503-12.
151. Sato H, Miyagawa Y, Okabe T, Miyajima M, Sunada H. Dissolution mechanism of diclofenac sodium from wax matrixgranules. J Pharm Sci 1997; 86(8): 929-34.
152. Siepmann F, Muschert S, Flament MP, Leterme P, Gayot A, Siepmann J. Controlled drug release from Gelucire-based matrixpellets: Experiment and theory. Int J Pharm 2006; 317: 136-43.
153. Thies R, Kleinebudde P. Melt pelletisation of a hygroscopic drug ina high shear mixer Part 1. Influence of process variables. Int JPharm 1999; 188: 131-43.
154. Thomsen LJ, Schaefer T, Kristensen HG. Prolonged release matrixpellets prepared by melt pelletization II. Hydrophobic substances asmeltable binders. Drug Dev Ind Pharm 1994; 20(7): 1179-97.
155. Thomsen LJ, Schæfer T, Sonnergaard JM, Kristensen HG. Prolonged release Matrix pellets prepared by melt pelletization I.Process variables. Drug Dev Ind Pharm 1993; 19(15): 1867-87.
156. Verhoeven E, Siepmann F, De Beer TRM, Van Loo D, Van denMooter G, Remon JP, et al. Modeling drug release from hot-meltextruded mini-matrices with constant and non-constant diffusivities.Eur J Pharm Biopharm 2009; 73: 292-301.
157. Voinovich D, Moneghinia M, Perissutti B, Filipovic-Grcic J, Grabnar I. Preparation in high-shear mixer of extended-releasepellets by melt pelletization. Int J Pharm 2000; 203: 235-44.
158. Young CR, Koleng JJ, McGinity JW. Production of sphericalpellets by a hot-melt extrusion and spheronization process. Int JPharm 2002; 242: 87-92.
159. Young CR, Koleng JJ, McGinity JW. Properties of drug-containingspherical pellets produced by hot-melt extrusion and spheronizationprocess. J Microencapsul 2003; 20(5): 613-25.
160. Young CR, Dietzsch C, McGinity JW. Compression of controlledreleasepellets produced by a hot-melt extrusion and spheronizationprocess. Pharm Dev Technol 2005; 10(1): 133-39.
161. Young CR, Dietzsch C, Cerea M, Farrell T, Fegely KA, Rajabi SA. Physicochemical characterization and mechanisms of release oftheophylline from melt-extruded dosage forms based on amethacrylic acid copolymer. Int J Pharm 2005; 301(1-2): 112-20.
162. Robinson, J.R., McGinity, J.W. Effervescent granules and methodsfor their preparation. US6071539 (2001) & US6488961 (2002).
163. McGinity, J.W., Robinson J.R., Delmas P. Effervescent granulesand methods for their preparation. WO0180822 (2000).
164. Breitenbach J. Melt extrusion: From process to drug deliverytechnology. Eur J Pharm Biopharm 2002: 54: 107-17.
165. Puaux JP, Bozga G, Ainser A. Residence time distribution in acorotating twin-screw extruder. Chem Eng Sci 2000; 55: 1641-51.
166. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, et al. Pharmaceutical applications of hot-melt extrusion:Part II. Drug Dev Ind Pharm 2007; 33: 1043-57.
167. Crowley M, Zhang F, Repka A, Thumma S, Upadhye S, KumarBattu S, et al. Pharmaceutical applications of hot-melt extrusion:Part I. Drug Dev Ind Pharm 2007; 33(9): 909-26.
168. Koleng, J.J., Mcginity J.W., Young C.R. Spherical particlesproduced by a hot-melt extrusion/spheronization process.WO2002035991 (2002).
169. Ghebre-Sellassie, I., Martin, C., Elliot B. Continuous meltspheronization apparatus and process for the production ofpharmaceutical pellets. US20070264328 (2007) & US20107771632(2010).
170. Oshlack, B., Chasin, M., Huang, H.P. Melt-extrusionmultiparticulates. US6706281 (2004).
171. Oshlack, B., Chasin, M., Huang, H.P., Sackler, D. Melt-extrudedorally administrable opioid formulations. US6743442 (2004).
172. Schaefer T, Mathiesen C. Melt pelletization in a high shear mixer.VIII. Effects of binder viscosity. Int J Pharm 1996; 139: 125-38.
173. Kleinebudde P, Knop K. Direct Pelletization of PharmaceuticalPellets in Fluid-Bed Processes. In Granulation, GranulationHandbook of Powder Technology Series. Elsevier: USA 2007; 11:779-811
174. Zhai H, Li S, Andrews G, Jones D, Bell S, Walker G. Nucleationand growth in fluidised hot melt granulation. Powder Technol 2009;189: 230-237.
175. Seo A, Holmb P, Schæfer T. Effects of droplet size and type ofbinder on the agglomerate growth mechanisms by meltagglomeration in a fluidised bed. Eur J Pharm Sci 2002; 16: 95-105.
176. Kristensen, H., Schaefer, T., Thomsen L.Ju., Kristensen, A. Processfor the preparation of extended release pellets. US5807583 (1998).
177. Miller, R.B., Leslie, S.T., Malkowska, S.T.A., Prater, D.A., Knott, T.J., Heafield, J., Challis, D. Substained release compositions and amethod of preparing pharmaceutical compositions. US5965163(1999).
178. N.K. Simultaneous encapsulation technique for use inpharmaceutical compositions US20060068011 (2006).
179. Barthelemy, P., Farah, N., Roussin, P. Immediate-release oral pelletcomprising polyglycolysed glycerides, and manufacturing process.US20030021844 (2003).
180. Shaw, K., Zhang, M. Ganaxolone formulations and methods for themaking and use thereof. WO2007062266 (2007).
181. Hudovornik, G., Vrecer, F., Pisek, R., Preskar, M., Kapele, T.Prolonged release multiparticulate pharmaceutical compositioncomprising Paliperidone. WO2010026254 (2010).
182. Rimkus, K., Muskulus, F., Brueck, S., Paetz, J. Pharmaceuticalcompositions comprizing 5-Chloro-N-({(5S)-2-Oxo-3-[4-(3-Oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid. WO2010003641 (2010).
183. Reo, J.P., Johnson, W.M. Tastemasked pharmaceutical system.US5891476 (1999).
184. Norling, T., Jensen, L.N., Hansen, J. Pharmaceutical multiple unitparticulate formulation in the form of coated cores. US5958458 (1999).
185. Benameur, H., Barthelemy, P. Method for coating solid particleswith a thermofusible agent, and resulting coated solid particles.US20030170312 (2003).
186. Snyder, H., Smith, A.E., Nasiatka, J. Apparatus and process toproduce particles having a narrow size distribution and particlesmade thereby. US20020071871 (2001).
187. Appel, L.E., Friesen, D.T., Lachapelle, E.D., Konagurthu, S., Falk, R.F., Reo, J.P. Taste-masked drugs in rupturing multiparticulates. US20070196483 (2007).
188. Chu, J.H., Shockey, J.R. Controlled released compositions.WO2009021127 (2009).
189. Faure, A., Voorspoels, J.F.M., Mertens, R.J.M., Kiekens, F.R.I. Process for the preparation of an intermediate powder formulationand a final solid dosage form under usage of a spray congealingstep. WO2009135680 (2009).
190. Duffield, A.J., Jackson, G., Frisbee, S. Pharmaceuticalcompositions with tetrabenazine. WO2010018408 (2010).
191. Patel, A.A., Palaniswamy, S., Davila, P. Multi-particulate,modified-release composition. US20060210631 (2006).
192. Cheboyina S, Chambliss WG, Wyandt CM. A novel freezepelletization technique for preparing matrix pellets. Pharm Tech 2004; 28(10): 98-110.
193. Cheboyina S, O'Haver J, Wyandt CM. A mathematical model topredict the size of the pellets formed in freeze pelletizationtechniques: Parameters affecting pellet size. J Pharm Sci 2006; 95:167-80.
194. Cheboyina S, Wyandt CM. Wax-based extended release matrixpellets prepared by a novel freeze pelletization technique II. In vitrodrug release studies and release mechanisms. Int J Pharm 2008a;359(1-2): 167-73.
195. Cheboyina S, Wyandt CM. Wax-based extended release matrixpellets prepared by a novel freeze pelletization technique I.Formulation and process variables affecting pellet characteristics.Int J Pharm 2008b; 359(1-2): 158-66.
196. Cheboyina, S., O'haver, J.H. Process and apparatus for producingspherical pellets using molten solid matrices. US7413690 (2008).
197. Dreu, R., Homar, M., Burjak, M., Kerc, J., Srcic, S. Hot - meltmicropellets. US20100172969 (2010).
198. Rekkas, D., Paterakis, P., Dallas, P. Method for the production ofpellets in a fluid bed rotor granulator using the melt pelletizationtechnique. GR1004855 (2005).
199. Vilhelmsen T, Kristensen J, Schæfer T. Melt pelletization withpolyethylene glycol in a rotary processor. Int J Pharm 2004; 275:141-53.
200. Fuisz Technologies. US Securities and Exchange Commission. FileNo 0-27082, 1997
201. Andrew, J., Jackson, G., Frisbee, S. Pharmaceutical compositionswith Tetrabenazine. WO2010018408 (2010).
202. Turchetta, S., Zenoni, M. Bupropion hydrobromide polymorphs.WO2010015692 (2010).
203. Jackson, G., Oberegger, W., Maes, Pa., Saleh, M.A. Bupropionhydrobromide and therapeutic applications. WO2009056550(2009).
204. Jackson, G., Nghiem, T. Multiparticulate osmotic delivery system.WO2008001341 (2008).
205. Mamajiwalla, S., Frisbee, S. Modified release formulations ofTramadol and uses thereof. WO2007078895 (2007).
206. Myers, M., Sanghvi, P.P. Product and method for the treatment ofHyperlipidemia. WO017774 (1999).
207. Mehta, A.M. Chrono delivery formulations and method of usethereof. WO2004091583 (2004).
208. Jee, U.K., Hwang, S.J., Park, J.K., Park, K.L., Moon, Y.G., Kwon, Y.J. Controlled release formulation comprising Benzimidazolederivatives or pharmaceutically acceptable salts therof withincreased stability and method for preparing the same.WO2004058257 (2004).
209. Vanderbist, F., Sereno, A., Baudier, P. Sustained releasecomposition contraining clarithromycin. US2004048814 (2004).
210. Brandon, M., Martinod, S. Extended release composition.WO2005117934 (2005).
211. Lee, S.J., Shin, H.J., Ki, M.H., Yoon, B.Y. Pharmaceutical pelletcompositions for controlled release. WO2005123138 (2005).
212. Mehta, A.M. Chrono delivery formulations and method of treatingatrial fibrillation. US6984402 (2006).
213. Shin, H.J., Lim, J.L., Nam, K.K. Stable controlled-release pelletcontaining Tolterodine. WO2007011131 (2007).
214. Boltri, L., Fabiani, F., Mapelli, L., Salvi, A., Magri, P., Nardi, A.,Villani, F. Lipoic acid pellets. WO2007138022 (2007).
215. Schlütermann, B., Kohlmeyer, M. Oral preparation with controlledrelease. WO2007073894 (2007).
216. Heinicke, G.W. Oral dosage formulations, methods of preparing thesame, and methods of reducing food effects on drug release.US20070243245 (2007).
217. Alles, R., Muskulus, F., Brück, S., Schulze Nahrup, J. Medicamentwith controlled release containing Galanthamine. WO2008064734(2008).
218. Chen, A.X., Kigin, P.D. Extended release compositions using waxlikematerials. US20080220079 (2008).
219. Venkatesh, G., Clevenger J.M. Modified release dosage forms ofskeletal muscle relaxants. US7544372 (2009).
220. Mcginity, J.W., Schilling, S.U. Hot-melt extrusion of modifiedrelease multi-particulates. US20100047340 (2010).
221. Chen, A.X., Kigin, P.D., Chen, H.L., Fan, J. Chewable extendedrelease formulations US20100062988 (2010).
222. Block J., Heim, S., Westerheide, R. Extended release vitamincomposition. WO2001072286 (2001).
223. Mulye, N. Controlled release pellet formulation. WO2001015668(2001).
224. Remon, J.P., Debunne A. Controlled release pharmaceutical pelletcompositions for reducing side effects of drug. WO2002028376(2002).
225. Strong, B., Kloemkes, M., Bachmann, D. Spherical pelletcontaining a water soluble active ingredient. WO2004002398(2004).
226. Kang, B.K., Chang, H.C., Lee, M.S. Extended release pelletscontaining Tamsulosin hydrochloride and processes for preparingthe same. WO2007117110 (2007).
227. Liversidge, G., Jenkins, S., Stark, P., Fanning, N.M.N., Rekhi, G.S., Devane, J.G. Modified release Ticlopidine compositions.US20090297597 (2009).
228. Liversidge, G., Jenkins, S., Devane, J.G., Stark, P., Fanning, N., Rekhi, G.S. Modified release Famciclovir compositions.US20100136106 (2010).
229. Debunne, A., Remon, J.P. Controlled release pharmaceutical pelletcompositions. EP1252886 (2002).
230. Mulye, N.V. Controlled release pellet formulation. WO2002017877(2002).
231. Zer, J., Ung K., Hwang, S.J., Park, J.K., Park, K.L., Moon, Y.G., Lee, S.B., Kwon, Y.J. Method of manufacturing controlled releaseformulation using pelletizer. WO2004058257 (2004).
232. Hayes, D., Lopore, A., Lukas, S., Quinn, E. Modified release coateddrug preparation. US20056958161 (2005).
233. Kohlmeyer, M., Schlütermann, B., Schroer, J. Oral preparation withcontrolled release of a Benzenesulphonamide. WO2007017253(2007).
234. Fekete, P., Budavári, Z., Újfalussy, G., Zsigmond, Z., Bozsó, Ág., Leventiszné Huszár, et al. Controlled release pharmaceuticalcompositions. WO2008102192 (2008).
235. Cheng, X., Cheng, X.X. Controlled release Tamsulosinhydrochloride formulation. WO2009002416 (2009).
236. Roy P, Shahiwala A. Review Multiparticulate formulation approachto pulsatile drug delivery: Current perspectives. J Control Release 2009; 134(2): 74-80.
237. Venkatesh, G., Clevenger, J.M. Modified release dosage forms ofskeletal muscle relaxants. US7790199 (2010).
238. Verma RK, Garg S. Current status of drug delivery technologiesand future directions. Pharm Tech 2001; 25(2): 1-14.
239. Landau, S.B., Miller, C.L., Fraser, M.O. Method of treating lowerurinary tract disorders. EP1795196 (2007).
240. Beckert, T., Petereit, H.U., Dressman, J., Rudolph, M. Multiparticulateform of medicament, comprising at least two differentlycoated forms of pellet. US6897205 (2005).
241. Kidane, A., Flanner, H., Bhatt, P., Raoufinia, A. Once daily dosageforms of trospium US7781448 (2007).
242. Chen, C.M., Cheng, X.X. Two pellet controlled release formulationfor water soluble drugs which contains an alkaline metal stearateenteric and delayed pellets. US20016270805 (2001).
243. Watts, P J., Smith, A., Bond, J.R., Lafferty W., Columbus, I.Floating drug delivery composition. WO2001058424 (2001).
244. Sungthongjeen S, Paeratakul O, Limmatvapirat S,Puttipipatkhachorn S. Preparation and in vitro evaluation of amultiple-unit floating drug delivery system based on gas formationtechnique. Int J Pharm 2006; 324(2): 136-43.
245. Frisbee, S.E., Getz, J., Cascone, J. Disintegratable microspheres.US6086920 (2000).
246. Kuhar, P., Svete, P., Sirca, J. Bursting Pellets. US20100034887(2010).
247. Remon, J.P. High release solid preparation, preparation and usethereof. US6368634 (2002).
248. Mezaache, N., Mezaache, D., Frisbee, S., Maes, P. Rapidabsorption selective 5-HT agonist formulations. WO2004073632(2004).
249. O'Toole, E., Fogarty, S. Sedative non-benzodiazepine formulations.WO2003059349 (2003) & WO2004062564 (2004).
250. Mezaache, N., Frisbee, S., Woodall, P., Herman, M. Quick dissolvecompositions and tablets based thereon. WO2004000197 (2004).
251. Phadke, N., Manente, M.B., Handique, K. Lyophilized pellets.WO2006119280 (2006) & US20070259348 (2007).
252. Balaxi M, Nikolakakis I, Malamataris S. Preparation of porousmicrocrystalline cellulose pellets by freeze-drying: Effects ofwetting liquid and initial freezing conditions. J Pharm Sci 2010;99(4): 2104-13.
253. Wagh MA, Dilip KP, Salunkhe1 KS, Chavan NV, Daga VR. Review techniques used in orally disintegrating drug deliverysystem. Int J Drug Deliv 2010; 2: 98-107.
254. Goel H, Rai P, Rana1 V, Tiwary1 AK. Orally disintegratingsystems: Innovations in formulation and technology. Recent PatDrug Deliv Formul 2008; 2: 258-74.
255. Karabelas, A. Use of Sabcomeline for the treatment of ADD orADHD. WO2010064047 (2010).
256. Shimizu, T., Morimoto, S., Tabata, T. Orally disintegrable tablets.WO059544 (1999).
257. Kurasawa, T., Watanabe, Y., Omachi, Y. Orally disintegratingpreparation. WO2009113703 (2009).
258. Fuisz, R., Yang, R., Myers, G. Uniform films for rapid dissolvedosage form incorporating taste-masking compositions.WO2003030883 (2003).
259. Seville PC, Li HY, Learoyd TP. Spray-dried powders forpulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 2007;24(4): 307-60.
260. G.W. Inhalation composition containing lactose pellets.US6955824 (2005).
261. Yoshida, H., Ito, H, Soeda, Y. Soft-pellet drug and process for thepreparation thereof. WO027911 (1999).
262. Tang B, Cheng G, Gu JC, Xu CH. Development of solid selfemulsifyingdrug delivery systems: Preparation techniques anddosage forms. Drug Discov Today 2008; 13: 606-12.
263. Shaji J, Jadhav D. Newer approaches to self emulsifying drugdelivery system. Int J Pharm Pharm Sci 2010; 2(1): 37-42.
264. Prajapati BG, Patel MM. Conventional and alternativepharmaceutical methods to improve oral bioavailability oflipophilic drugs. Asian J Pharm 2007; 1: 1-8.
265. Gao, P., Morozowich, W., Shenoy, N. Self-emulsifying drugdelivery systems for extremely water-insoluble, lipophilic drugs.WO2002007712 (2002) & US20020119198 (2002).
266. Yu, Z., Huth, S.W., Crawford, L.L., Cook, J.N. Self-emulsifyingcompositions, methods of use and preparation. WO2004082625(2004).
267. Yu, Z.J., Huth, S. Drug emulsifying compositions, Self-emulsifyingmethods of use and preparation. US20040185068 (2004).
268. Wu, B., Huang, Y. Multiphase drug delivery system.US20100151036 (2010).
269. Moodley, J., Coulter, I. Minicapsule formulations. WO2006035416(2006).
270. Booth, S.W., Clarke, A., Newton, J.M. Spheronized selfemulsifyingsystem for hydrophobic and water-sensitive agents useof MCC and an extrusion spheronization process. US6630150(2003).
271. Berndl, G., Breitenbach, J., Heger, R., Stadler, M., Wilke, P., Rosenberg, J. Self-emulsifying active substance formulation anduse of this formulation. US20040013697 (2004).
272. Obeidat WM. Recent Patents review in microencapsulation ofpharmaceuticals using the emulsion solvent removal methods.Recent Pat Drug Deliv Formul 2009; 3: 178-92.
273. De Nijs, H. Contraceptive implant. US5088505 (1992).
274. Tormala, P, Suokas, E., Aro, H., Koort, J. Bioabsorbable drugdelivery system for local treatment and prevention of infections.US6579533 (2003).
275. Khullar P, Kulkarni A, Jaiswal N. Pharmaceutical Pellets: Industrialapplications & Innovative perspective. Pharma Times 2010; 42.
276. The Merck manuals online medical library. Available at http://www.merck.com/mmpe/sec02/ch012/ch012b.html (Accessedon: Nov. 06, 2010).
277. Gupta P, Gupta K. Broken tablets: Does the sum of the parts equalthe whole? Am J Hosp Pharm 1988; 45: 1498.
278. Myriam S, Philippe A, Fontan JE, Brion F. Splitting tablets in half.Am J Hosp Pharm 1994; 15548-550.
279. Kristensen HG, Jorgensen GH, Sonnegaard JM. Mass uniformity oftablets broken by hand. Pharmeuropa 1995; 7: 298-302.
280. Mc Devitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting.Pharmacotherapy 1998; 18: 193-7.
281. Breitkreutz J, Wessel T, Boos J. Dosage forms for peroral drugadministration to children. Pediatr Perinat Drug Ther 1999; 3: 25-33.
282. Nahata MC. Pediatric drug formulation: Challenges and potentialsolutions. Ann Pharmacother 1999; 33, 247-49.
283. Choonara IS, Conroy S. Unlicensed and off-label drug use inchildren: Implication for safety. Drug Saf 2002; 25: 1-5.
284. Kayumba PC, Huyghebaert N, Cordella C, Ntawukuliryayo JD, Vervaet C, Remon JP. Quinine sulphate pellets for flexible pediatricdrug dosing: Formulation development and evaluation of tastemaskingefficiency using the electronic tongue. Eur J PharmBiopharm 2007; 66: 460-65.
285. EMA Reflection Paper. Formulations of choice for the paediatricpopulation 2006.
286. Cram A, Breitkreutz J, Desset-Brèthes S, Nunn T, Tuleu C.European Paediatric Formulation Initiative (EuPFI). Challenges ofdeveloping palatable oral paediatric formulations. Int J Pharm 2009;365(1-2): 1-3.
287. Bar-Shalom, D. Controlled release composition. WO022962 (1995)& WO051208 (1999).
288. Fischer, G., Bar-Shalom, D., Slot, L., Lademann, A.M. MatrixCompositions for controlled delivery of drug substances.WO2004084869 (2004).
289. Dobson K. Method and apparatus for dispensing medication.US7543766 (2009).